A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

NCT04578847 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

NETWORK

Sponsor class

Conditions

Chronic Myeloid Leukemia
Chronic Myeloid Leukemia in Remission
BCR-ABL Positive Chronic Myelogenous Leukemia

Interventions

DRUG: Imatinib
DRUG: Nilotinib
DRUG: Dasatinib
DRUG: Bosutinib

Sponsor

National Research Center for Hematology, Russia